SZA Schilling, Zutt & Anschütz advises Luxempart on the acquisition of shares in Medios AG

SZA Schilling, Zutt & Anschütz, with a team led by Dr. Christoph Nolden, has advised the Luxembourg investment company Luxempart S.A. on the acquisition of a block of shares in Medios AG.

With the strategic investment in Medios AG, Luxempart has acquired a 14.90 percent stake from Manfred Schneider, the founder of Medios AG. This transaction settles the succession of Manfred Schneider as a shareholder and establishes Luxempart as a new strategic anchor shareholder in Medios AG. SZA Schilling, Zutt & Anschütz regularly advises Luxempart on investment and participation issues relating to its listed portfolio companies.

Luxempart S.A. is a listed investment company with a net worth of over EUR 2.3 billion. With permanent capital and a professional investment team, Luxempart provides companies, families and executives flexible long-term financing solutions and actively supports its portfolio companies in their growth and international expansion.

Medios AG is a listed Berlin-based pharmaceutical company specializing in the production and distribution of patient-specific pharmaceuticals for chronic and rare diseases.

SZA Schilling, Zutt & Anschütz:

Dr. Christoph Nolden (Lead, M&A, Capital Market Law, Frankfurt), Dr. Stephanie Birmanns (Foreign Trade Law, Antitrust & Competition Law, Brussels), Benedict Blechschmidt (M&A, Corporate Law, Frankfurt).